PT-141 Protocol

Evidence Level: Established Evidence

Backed by a substantial human clinical trial base, often with regulatory authorization for a specific indication.

Human evidence: Randomized controlled trials supporting FDA approval for hypoactive sexual desire disorder in premenopausal women.

Animal evidence: Preclinical melanocortin-receptor pharmacology preceding human trials.

Introduction & Mechanism of Action

Melanocortin-receptor agonist (bremelanotide) studied for sexual arousal disorders; one formulation is FDA-approved for a specific indication.

Melanocortin-4 receptor agonist studied for central (brain-mediated) rather than vascular sexual-arousal pathways, distinguishing its research angle from PDE5-inhibitor-class approaches.

Receptors/targets: Melanocortin-4 receptor (MC4R)

Areas of Research Interest

• Sexual-arousal-disorder research
• Melanocortin-pathway studies

Benefits Reported in Research

• Sexual-arousal research
• Melanocortin-pathway studies

Reported Research Dosing Range

The figures below are cited from published research literature and protocol references — they describe what has been studied, not a personal prescription or instruction.

Reported range: 1–2 mg

Reported frequency: Structured dosing data unavailable

Reported cycle duration: Structured dosing data unavailable

Escalation & maintenance: A dedicated weekly escalation and maintenance schedule specific to this peptide has not yet been published here — follow the dose range and frequency above, titrating conservatively from the low end, and consult a physician before adjusting.

Research Reference Data

Published research on PT-141 reports administration at 1–2 mg via subcutaneous route. The table below cites that published research — it is not an individualized instruction.

Reconstitution Reference

Published research protocols reconstitute a 10 mg vial with 2 mL bacteriostatic water, yielding a concentration of 5.00 mg/mL. This is cited reference information, not a personalized preparation instruction — use the general research calculator below for your own reference computation.

Research Protocol Timeline

A reference summary of how this compound is described across published research — formulation, reported administration, and reported cycle length.

Dilution Guide

Reconstitute with 2 mL bacteriostatic water

Bacteriostatic Water (BAC Water) is the only recommended diluent. Do not dilute with sterile water, normal saline, lidocaine, or any other solution unless explicitly specified by the manufacturer.

Handling Guide

General laboratory handling practice cited for reference — not a personalized instruction. Any human use should follow the guidance of a licensed physician.

Wash hands and clean the injection site with an alcohol swab. Pinch a fold of skin and insert the needle at a 45–90° angle for standard subcutaneous injection (abdomen, thigh, or upper arm). Inject slowly, withdraw, and apply gentle pressure. Rotate injection sites to reduce irritation, and dispose of needles in an approved sharps container.

Storage

Store lyophilized (powder) vials in a freezer at -20°C, protected from light. Once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within the timeframe recommended in your supplier documentation — typically 2–4 weeks.

Monitoring

Monitor for injection-site reactions and the side effects listed above. Stop use and consult a physician if severe or persistent reactions occur. This is a general monitoring guideline, not a personalized medical monitoring plan.

Side Effects

• Nausea
• Flushing
• Headache
• Injection-site reaction
• Transient blood-pressure elevation

Contraindications

• Uncontrolled hypertension or known cardiovascular disease
• Pregnancy

Drug interactions

• Naltrexone — labeled interaction for the approved formulation
• Other blood-pressure-affecting medications — theoretical additive effect

Safety

• Nausea is a commonly reported effect, particularly at higher doses
• Transient blood-pressure elevation reported in trials

Approval covers one specific indication and population; off-label or compounded use carries a different risk/evidence profile.

Expected Results & Comparison

PT-141 has the stronger, FDA-backed evidence base of the two melanocortin-related compounds in this catalog for a specific indication (premenopausal hypoactive sexual desire disorder). Melanotan II hits a broader set of melanocortin receptors and has libido-related research interest, but lacks a comparable approved indication or trial base.

References

Continue